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This review discusses the challenges of chemotherapy for human African trypanosomiasis (HAT). The few drugs registered for
use against the disease are unsatisfactory for a number of reasons. HAT has two stages. In stage 1 the parasites proliferate in the
haemolymphatic system. In stage 2 they invade the central nervous system and brain provoking progressive neurological
dysfunction leading to symptoms that include the disrupted sleep wake patterns that give HAT its more common name of
sleeping sickness. Targeting drugs to the central nervous system offers many challenges. However, it is the cost of drug
development for diseases like HAT, that afflict exclusively people of the world’s poorest populations, that has been the principal
barrier to new drug development and has led to them becoming neglected. Here we review drugs currently registered for HAT,
and also discuss the few compounds progressing through clinical trials. Finally we report on new initiatives that might allow
progress to be made in developing new and satisfactory drugs for this terrible disease.
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Introduction
Human African trypanosomiasis (HAT), perhaps better
known as sleeping sickness once the causative trypanosome
parasites have established within the central nervous system
(CNS) (Barrett et al., 2003), is considered as a neglected
disease (Remme et al., 2002). Neglected diseases are those
ailments which affect people from among the world’s
poorest populations, for which satisfactory treatment does
not exist, but for which the investment required to bring
new compounds to market has proven a major disincentive
to drug development.
At the end of the twentieth century, nearly half a million
people were estimated to be afflicted by HAT (Barrett et al.,
2003). Ironically, trypanosomes were among the first organ-
isms to be targeted by synthetic drugs and Paul Ehrlich, ‘the
father of chemotherapy’ (Drews, 2004), chose these organ-
isms as a model on which to test his ideas. During the first
two-thirds of the twentieth century, several compounds were
introduced to treat HAT (Williamson, 1962, 1970; Apted,
1970). Sanofi-Aventis and Bayer between them currently
produce all of the licensed anti-HAT drugs and donate them
free of charge to the World Health Organization (WHO) who
distributes them in Africa.
The African trypanosome is a popular organism for
biological research. Much is known about trypanosome
biochemistry and its genome sequence was published in
2005 (Berriman et al., 2005). The parasite is amenable to drug
target validation through genetic means (Barrett et al., 1999)
and simple screens are available to test drugs (for example,
Raz et al., 1997). However, only a single compound,
eflornithine, has been registered for use against HAT in the
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last 50 years, a reflection of the gap between our under-
standing about the organism and our capacity to develop
new drugs. New initiatives discussed in the final part of this
review promise to close the gap.
Two subspecies of the Kinetoplastid protozoans,
Trypanosoma brucei, cause human disease. T. b. rhodesiense is
responsible for an acute form in Eastern and Southern Africa
(Fevre et al., 2005), while T. b. gambiense causes a chronic
form in West and Central Africa (Figure 1). Generally the
rhodesiense form of the disease is fatal within weeks to
months of inoculation through the bite of an infected tsetse
fly vector (Figure 2), while the gambiense form takes years to
develop. There appears to be some geographical variance in
disease manifestation. For example, in Malawi, patients
carry T. b. rhodesiense and yet harbour the parasites without
their causing CNS-involved disease for many years (MacLean
et al., 2004). Sporadic reports of other trypanosome species
causing disease in humans have appeared. These include
T. congolense (Truc et al., 1998) and T. evansi (Joshi et al., 2005),
which normally infect only animals. Generally, however, a
non-immune mechanism of killing, involving a trypano-
some lytic factor, believed to be apolipoprotein L1 (apoL1)
(Pays et al., 2006) and possibly other components of high-
density lipoprotein fractions (Smith et al., 1995), prevents
most species of African trypanosome from establishing
infections in humans. The single reported case of a T. evansi
infection in man involved a patient who lacked apoL1
(Vanhollebeke et al., 2006). T. b. gambiense was responsible
for the epidemics that marked the end of the twentieth
century. A concerted WHO-led campaign to bring the disease
under control has made an impact in recent years reducing
the number of cases significantly (Barrett, 2006; Anon-
ymous, 2006).
Animal reservoirs play an important role in the epidemiol-
ogy of T. b. rhodesiense, but are less important for T. b.
gambiense although both wild (Njiokou et al., 2006) and
domestic (Simo et al., 2006) animals have been found
infected with this subspecies. Vector control can curb
transmission (Allsopp, 2001) and was successfully employed
in recent years to eradicate trypanosomiasis from Zanzibar
using extensive trapping, followed by the sterile insect
technique (Vreysen et al., 2000). However, it has proven
difficult to implement tsetse control in a coordinated
fashion on the African mainland. A process of antigenic
variation, where parasites repeatedly change the surface coat
that interfaces with the immune system, renders the
prospects of vaccination poor (McCulloch, 2004). Drugs are
central to efforts to control HAT.
Current drugs (Pepin and Milord, 1994; Barrett, 2000;
Legros et al., 2002; Fairlamb, 2003; Burri et al., 2004; Brun
and Balmer, 2006) all suffer drawbacks. Toxicity (sometimes
severe), the need for parenteral administration, lack of a
guaranteed supply and increasing incidence of treatment
failure with some drugs make the situation difficult. The
only compound in advanced phase III clinical trials is the
orally available prodrug, pafuramidine maleate (DB289)
(Boykin et al., 1996; Ansede et al., 2004), which is
metabolized systemically to the diamidine, furamidine
(DB75). It is the first compound whose development as a
trypanocide might be considered to have approached that
typical for registration of a new chemical entity for
therapeutic purposes today. However, it is active only in
stage 1 disease. Other drugs are urgently required, especially
for stage 2 patients as it is generally only this cohort who
present at HAT clinics once neurological symptoms are
manifest. This review discusses those drugs already in use for
HAT and also the few compounds in different stages of the
development process, leading to a discussion of new
initiatives in drug development for HAT.
Drugs registered for HAT chemotherapy
Four licensed compounds are used against HAT today,
depending on the causative subspecies and whether parasites
have initiated disease of the CNS (stage 2) or not (stage 1)
(Pepin and Milord, 1994; Denise and Barrett, 2001; Keiser
et al., 2001; Fairlamb, 2003; Burri et al., 2004; Brun and
Balmer, 2006). Two compounds are used against stage 1
disease: suramin and pentamidine. Against stage 2 disease,
melarsoprol (active against T. b. gambiense and T. b.
rhodesiense) and eflornithine (only useful against T. b.
gambiense) can be used. Nifurtimox, alone or in combination
with other drugs, particularly with eflornithine, is being
considered as an option for melarsoprol-refractory late-stage
disease, or even more widely (Priotto et al., 2006).
Figure 1 A map of countries infected with HAT. The countries
shown in colour have historically reported HAT. Those countries
coloured in red are currently reporting in excess of 1000 cases per
year. Those in brown currently report between 50 and 1000 cases
per year. Those in blue report fewer than 50 cases per year, while
those in green currently report no cases of HAT. Nearly 97% of all
reported cases are caused by T. b. gambiense. T. b. rhodesiense is
found in East and Southern Africa. (Figure courtesy of Dr Pere
Simarro at the World Health Organization.) HAT, human African
trypanosomiasis.
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Drugs used in early-stage disease
Provided HAT is diagnosed sufficiently early, suramin or
pentamidine can be used. Their ease of administration and
relative safety make them preferable to drugs used for stage 2
disease. The rapidly proliferating parasitaemia typical of the
rhodesiense form of the disease can provoke early presenta-
tion by patients at clinic. However, the symptoms of early-
stage gambiense disease do not normally extend beyond a
general malaise common place in rural Africa. These patients
are unlikely to present passively before late-stage involve-
ment. Efforts to improve diagnosis (Chappuis et al., 2005a)
are needed to accompany improved treatment.
Pentamidine
Background. Pentamidine isethionate (Figure 3) is currently
produced by Sanofi-Aventis as pentacarinat in 200 mg
ampoules for intramuscular injection. It is used against
gambiense disease but not usually rhodesiense. The drug is
donated, free of charge, to WHO for distribution. Four
milligrams per kilogram given daily, or on alternate days,
Figure 2 The life cycle of Trypanosoma brucei. Parasites are transmitted to man by the bite of an infected tsetse fly. Within man, the parasites
proliferate first within the haemolymphatic system and later invade the CNS. Proliferative bloodstream slender form parasites (a), transform via
an intermediate form (b) into non-proliferative stumpy forms (c). These are pre-adapted to survive within a tsetse fly where they transform into
procyclic forms (d) that proliferate in the midgut of this environment before passing through various other stages including the epimastigote
form (e) until transforming into metacyclic trypomastigotes (f) in the salivary glands. These forms are preadapted for life in the mammalian
host when injected during a bloodmeal. Forms that are capable of division are labelled with a D. CNS, central nervous system.
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for 7–10 days are typical schedules (Sands et al., 1985; Burri
et al., 2004).
Modes of action and resistance mechanisms. Pentamidine is
concentrated to high levels (in the low millimolar range) by
trypanosomes exposed to low micromolar concentrations of
the drug (Damper and Patton, 1976a; Berger et al., 1995;
Carter et al., 1995; de Koning, 2001a; Bray et al., 2003).
Uptake is carrier mediated (Damper and Patton, 1976b). The
drug enters principally via the P2 aminopurine permease
which also transports melaminophenyl arsenicals (Carter
et al., 1995). A high-affinity pentamidine transporter 1
(HAPT1) and a low-affinity pentamidine transporter 1
(LAPT1) also contribute to pentamidine uptake (de Koning,
2001a); hence parasites selected for melaminophenyl arseni-
cal resistance that lack the P2 transporter often remain
sensitive to pentamidine (Frommel and Balber, 1987; Fair-
lamb et al., 1992a; de Koning, 2001b; Matovu et al., 2003).
One laboratory line selected for pentamidine resistance
continued to accumulate drug to high levels and retained
activity of the P2 transporter (Berger et al., 1995). This
parasite line was of much reduced virulence in rodents,
which might indicate that the development of resistance to
pentamidine is associated with substantial fitness costs,
rendering the propagation of resistant lines in the field
unlikely (Berger et al., 1995; Bray et al., 2003). Another line,
this time selected for pentamidine resistance in a cell line
already lacking the P2 transporter (TbAT1, T. brucei adeno-
sine transporter 1) (Matovu et al., 2003), also developed a
reduced virulence phenotype, but on this occasion penta-
midine uptake was greatly reduced and the HAPT1 transpor-
ter was reported to be lost (Bridges et al., 2007).
While pentamidine’s uptake into trypanosomes has been
characterized in detail, its definitive mode of action is not
certain (Berger et al., 1993; Werbovetz, 2006). The mitochon-
drion appears to be a target for pentamidine in various
species including yeast (Ludewig et al., 1994). In Leishmania
parasites (close relatives of trypanosomes), fluorescent
analogues of pentamidine accumulate preferentially in this
compartment and mitochondrial damage (Hentzer and
Kobayasi, 1977; Croft and Brazil, 1982) precedes cell death.
Pentamidine resistance in Leishmania correlates to a reduc-
tion in the mitochondrial membrane potential (Basselin and
Robert-Gero, 1998; Basselin et al., 2002; Mukherjee et al.,
2006). As a di-cation, pentamidine interacts electrostatically
with cellular polyanions. It binds DNA, including the unique
intercatenated network of circular DNA molecules termed
the kinetoplast, which make up the mitochondrial genome
of all kinetoplastid flagellates (Simpson, 1986). However,
bloodstream form T. brucei can retain viability, given time to
adapt, when the kinetoplast has disintegrated (a state termed
dyskinetoplastidy (Schnaufer et al., 2002)), although mito-
chondrial DNA can remain dispersed within the mitochon-
drion in some of these cases. Dyskinetoplastic parasites are
slightly less sensitive than wild-type cells to diamidines.
Fluorescent diamidines, for example, furamidine (Stewart
et al., 2005; Mathis et al., 2006) and stilbamidine (Hawking
and Smiles, 1941) also accumulate rapidly in the kinetoplast,
and they also sequester in another class of organelle believed
to be acidocalcisomes (Mathis et al., 2006). Whether the
localization correlates with activity is not certain. Another
suspected target, S-adenosylmethionine decarboxylase, was
ruled out because Leishmania parasites overexpressing this
enzyme are equally susceptible to pentamidine as wild-type
cells (Roberts et al., 2006).
Pharmacology. Pentamidine’s use against Pneumocystis carinii
pneumonia in AIDS (acquired immunodeficiency syndrome)
patients has contributed to the increased interest in under-
standing the pharmacokinetics of the drug (Conte, 1991).
Other studies have looked specifically at the situation in HAT
patients (Bronner et al., 1991). The drug has a large volume
of distribution and long terminal half-life (elimination times
running into weeks after a typical course). Extensive tissue
retention and binding to serum proteins contribute to this.
The long half-life of pentamidine explains why the drug had
some success in prophylactic campaigns in west and central
Africa in the mid-twentieth century (Waddy, 1970), a
practice that is no longer recommended.
The drug is given by injection because, as expected for a
highly charged molecule (pKa of 11.4), pentamidine is not
readily absorbed from the intestine. Intramuscular injection
is preferred over intravenous injection since this latter route
is associated with increased risk of hypotension. Although
generally useful only in stage 1 disease, pentamidine might
have some activity against parasites in cerebrospinal fluid
(CSF), in what has been called ‘early-late-stage disease’,
when white cell counts are still low (appearance of white
blood cells in CSF accompanies stage 2 disease) and parasites
have only recently entered CSF (Doua et al., 1996). Low levels
of pentamidine (below 1% of plasma levels) have been
measured in CSF (Bronner et al., 1991). Pentamidine is
extensively metabolized (Berger et al., 1992) with cyto-
chrome P450-dependent oxygenases playing a key role.
The drug is quite toxic. Lowering of blood glucose levels is
common with hypotension evident in 10% of treated cases.
Other toxic effects include pain at the site of injection,
nephrotoxicity, leucopenia and liver enzyme abnormalities
(Sands et al., 1985; Doua and Yapo, 1993).
Figure 3 Structures of some important trypanocidal diamidines.
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Pentamidine is highly trypanocidal (with IC50 values
in vitro in the order of 1–10 nM in a typical 3-day drug
sensitivity assay). The time required to kill the parasites is
dependent on dose with increasing doses causing progres-
sively faster killing (Miezan et al., 1994).
Given the drug’s toxicity, decreasing overall exposure is
desirable. Since parasites are killed on exposure to just 10 nM
for 3 days, and since pentamidine’s pharmacokinetics
ensures concentrations several orders of magnitude above
this level are maintained for several days after the termina-
tion of drug administration, the prospects of using a 3-day
course are currently being investigated.
Suramin
Background. Suramin (Figure 4) is a polysulphonated sym-
metrical naphthalene derivative and was first used against
sleeping sickness in 1922 (Voogd et al., 1993). This followed
Ehrlich’s demonstration that other naphthalene dyes had
trypanocidal activity due to selective accumulation by
trypanosomes (trypan blue, named for its trypanocidal
activity, is still used in mammalian cell viability assays). As
there is renal clearance of these naphthalenes, suramin’s
colourlessness was an important factor behind its develop-
ment. Suramin is currently donated to WHO by Bayer as
Germanin (Bayer 205). Reports of treatment failures from
gambiense foci in the 1950s and the fact that pentamidine is
easier to administer led to suramin being used mainly for
rhodesiense cases today. The drug has been considered for
other conditions, particularly in androgen-independent
prostate cancer (Kaur et al., 2002). The fact that the drug
inhibited retroviral reverse transcriptase (Mitsuya et al.,
1984) and also interfered with HIV binding to CD4þ cells
led to well-publicized, but unsuccessful, trials against HIV/
AIDS.
Modes of action and resistance mechanisms. Many hypotheses
as to suramin’s mode of trypanocidal action have been
proposed, but none proven. With six negative charges, the
drug binds, by electrostatic interaction, to many enzymes.
Suramin is around a hundred fold less active against
procyclic form trypanosomes, that normally reside in tsetse
flies, than against bloodstream forms (Scott et al., 1996).
Since glycolysis is essential to bloodstream forms but not
procyclic forms (Fairlamb and Bowman, 1977, 1980; Besteiro
et al., 2005) and because suramin inhibits a number of
glycolytic enzymes (Wierenga et al., 1987), glycolysis has
been proposed as a likely target. However, any number of
other pathways too could be targeted by the drug. For
example, it is a competitive inhibitor of 6-phosphogluconate
dehydrogenase, an enzyme of the pentose phosphate path-
way (Hanau et al., 1996).
Endocytosis appears to be the most likely route of entry
(Fairlamb and Bowman, 1980). Because of its high avidity
binding to many serum proteins, including low-density
lipoprotein (LDL) (Vansterkenburg et al., 1993), it was
suggested that it might enter while bound to LDL (Bastin
et al., 1996; Coppens and Courtoy, 2000; Green et al., 2003).
However, in procyclic cells, at least, manipulation of
different vesicular transport systems affects uptake of LDL
and suramin independently of each other (Pal et al., 2002).
The extremely high rate of fluid-phase endocytosis displayed
by bloodstream form trypanosomes (Engstler et al., 2004)
could potentially explain uptake parameters of suramin into
T. brucei without a requirement for a particular receptor,
although this is untested.
Reports on suramin resistance in the field are rare (Barrett,
2003). However, resistance can be selected readily in the
laboratory (Scott et al., 1996). The drug is also employed as a
veterinary trypanocide and resistance has been noted in
species of trypanosome, for example, T. evansi, that infect
animals (Mutugi et al., 1994; El Rayah et al., 1999) although
mechanisms of resistance are not understood.
Pharmacology. Poor intestinal absorption and a local irrita-
tion if given intramuscularly mean that suramin is best given
by slow intravenous injection (Voogd et al., 1993). A course
of five injections, every 3–7 days, over a 4-week period is
typical. Most of the drug (499%) binds to serum proteins.
Suramin does not cross the blood–brain barrier to levels
capable of killing trypanosomes in the CSF at doses given in
treatment of stage 1 disease (although in mice, very large
doses (480 mg kg1) are capable of curing a stage 2 model of
the disease (Jennings, 1995)).
The use of the drug in AIDS and cancer clinical trials
improved knowledge of its pharmacology (Collins et al.,
1986). The elimination terminal half-life is very long (for
example, 41–78 days was reported in one study (Eisenberger
and Reyno, 1994)).
In vitro, exposure to 1mg kg1 for 24 h is sufficient to kill
trypanosomes. Thus with levels higher than 100 mg ml1 for
several weeks after a typical course the drug’s success in
prophylaxis is understandable (Waddy, 1970) although no
longer used.
At concentrations higher than 350 mg ml1, the drug
induced significant neurotoxicity (Kaur et al., 2002) and
even at lower concentrations neurotoxic effects were evident
Figure 4 Structures of suramin, trypan blue and some important
trypanocidal arsenicals.
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(Bitton et al., 1995). Neuropathy, rash, fatigue, anaemia,
hyperglycaemia, hypocalcaemia, coagulopathies, neutropae-
nia, renal insufficiency and transaminitis are all common.
The adverse effects reported with suramin were sufficient for
the US Food and Drug Administration to block approval for
use in prostate cancer (Kaur et al., 2002), although HAT
regimens are short enough to make safety tolerable.
Drugs used in late-stage disease
Stage 2 of HAT involves progressive breakdown of neurolo-
gical function, including the alteration in sleep-wake
patterns that defines ‘sleeping sickness’. In fact, patients do
not sleep more than healthy subjects, but the disrupted sleep
patterns often manifest themselves in daytime somnolence
(Buguet et al., 1993). Alterations in the ‘sleep onset rapid eye
movement sleep periods’ may become a new tool to detect
CNS involvement and 2nd stage disease (Buguet et al., 2005).
Since the late stage is characterized by the presence of
parasites within the cerebral spinal fluid and brain, any drug
that is to reach the parasites must first cross the blood–brain
barrier or the blood–CSF barrier (Croft, 1999; Enanga et al.,
2002; Kennedy, 2006). Many chemicals that show good
activity against models of stage 1 disease fail to cure models
of stage 2 disease (Jennings et al., 1977; Bouteille et al., 1998)
due to the difficulty of getting molecules to cross the blood–
brain barrier.
Melarsoprol
Background. Melarsoprol (Figure 4), a melaminophenyl-
based organic arsenical, was introduced in 1949 (Friedheim,
1949). It remains the most widely used drug against late-
stage HAT in spite of extremely toxic side effects. In the order
of 5–10% of patients taking melarsoprol suffer a reactive
encephalopathy (Robertson, 1963; Pepin and Milord, 1994;
Blum et al., 2001, 2006); half of these die!
Melarsoprol is the only available compound capable of
treating stage 2 T. b. rhodesiense disease and the only
generally affordable compound to treat stage 2 gambiense
disease. It is administered as a 3.6% solution in propylene
glycol and distributed in 5 ml ampoules for intravenous
injection. The drug is provided by Sanofi-Aventis free to
WHO for distribution and will continue to be provided for at
least 5 more years.
Modes of action and resistance mechanisms. It is not known
how arsenicals kill trypanosomes. When exposed to melar-
soprol, the parasites lyse rapidly (Meshnick et al., 1978). Loss
of ATP due to inhibition of glycolysis could underlie lysis
although it seems that the cells lyse before ATP supplies are
seriously depleted (Vanschaftingen et al., 1987). Arsenic
forms stable interactions with thiols including trypa-
nothione (Fairlamb et al., 1989), a key low molecular weight
thiol (a bis-glutathionyl-spermidine adduct) found in trypa-
nosomatids but not in mammalian cells (Fairlamb et al.,
1985) and lipoic acid (Fairlamb et al., 1992b). Whether these
interactions underlie trypanocidal activity is, however, not
known.
In several foci, treatment failures have reached levels of
30% of those treated (Legros et al., 1999; Brun et al., 2001;
Moore and Richer, 2001; Stanghellini and Josenando, 2001).
Most parasites selected for resistance to melamine-based
arsenicals in the laboratory have lost the P2 aminopurine
transporter that carries the drug (Carter and Fairlamb, 1993;
Barrett and Fairlamb, 1999; Mäser et al., 1999; Stewart et al.,
2005) and several parasites isolated from relapse cases in the
field are also defective in P2 transport (Mäser et al., 1999;
Matovu et al., 2001; Stewart et al., 2005). No significant
difference in intrathecal accumulation of drug between
successfully treated and relapsing patients was seen (Brun
et al., 2001), although the demonstration of parasite
resistance in the field has been hampered by difficulties in
retrieving T. b. gambiense from patients for study. Parasitea-
mias are generally very low and it is difficult to establish
infections in vitro or in rodents. Cryopreservatives like
Triladyl (Maina et al., 2006), and African rodent species that
are relatively sensitive to T. b. gambiense parasites (Buscher
et al., 2005; Maina et al., 2007), currently offer hope that
collection of samples from the field can be improved.
In vitro, unmetabolized melarsoprol is believed to cross
membranes by passive diffusion (Scott et al., 1997). Melarsen
oxide, however, enters T. brucei principally by the P2
aminopurine transporter (Carter and Fairlamb, 1993) en-
coded by the tbat1 gene (Mäser et al., 1999). However,
trypanosomes from which the tbat1 gene has been removed
are only marginally less sensitive to melamine-based arseni-
cals than are wild-type cells (Matovu et al., 2003), indicating
that secondary routes of uptake exist and loss of P2 plus
these secondary routes is required for high-level resistance.
Low concentrations of pentamidine inhibited a secondary,
slow lysis of trypanosomes in a spectrophotometric test
(Matovu et al., 2003), prompting suggestions that the HAPT1
(de Koning, 2001a) might be the second route of entry for
melarsen oxide. Moreover, the highly pentamidine resistant
line derived from the tbat1 gene knockout line was also
highly resistant to melarsen oxide and had lost the HAPT1
transporter (Bridges et al., 2007). However, since trypano-
somes selected for high-level melarsen resistance retain
sensitivity to pentamidine (Fairlamb et al., 1989b), it is clear
that more is yet to be learned about all possible routes of
uptake of these different classes of drug. Ectopic over-
expression of the tbmrpa gene, that encodes a P-glycoprotein
type pump, is capable of inducing melarsoprol resistance
(Shahi et al., 2002).
Patients are currently treated and then subjected to follow-
up for 2 years. Any recurrence of the disease over that time is
considered as a treatment failure. The possibility of identify-
ing trypanosomes that lack the P2 transporter as being
melarsoprol refractory at the time of disease diagnosis has
clear benefits. Tests using fluorescent diamidines (for
example, furamidine) that enter via the P2 transporter can
identify loss of the P2 transporter and these offer potential as
a major advance in diagnosis of resistance in the field
(Stewart et al., 2005).
Pharmacology. Treatment schedules with melarsoprol
show how an understanding of pharmacokinetics can lead
to radical improvements in drug regimens. A standardized
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10-day course with 2.2 mg kg1 given once a day is as
effective as older protocols (Burri et al., 2000; Schmid et al.,
2004, 2005; Pepin and Mpia, 2006). Melarsoprol was
introduced to replace tryparsamide, another arsenical.
Tryparsamide administration regimens took into account
toxicity associated with drug accumulation in various tissues
(Williamson, 1970). It was given over prolonged periods,
interspersed with ‘rest’ periods to enable clearance of drug
from tissue deposits. Similar regimens were unnecessarily
retained for melarsoprol before implementation of the 10-
day course.
First studies into melarsoprol’s pharmacokinetics em-
ployed a bioassay (Hawking, 1962; Burri and Brun, 1992)
based on in vitro trypanocidal activity found in various body
fluids containing drug. HPLC methods (Bronner et al., 1998)
that measure melarsoprol itself failed to identify the key
active metabolite, melarsen oxide, which forms rapidly in
plasma (96% clearance within 1 h). Much of the drug is
bound to plasma protein. A mean elimination half-life of
3.5 h for active metabolite was determined (Burri and Brun,
1992; Burri et al., 1993).
Melarsoprol (or melarsen oxide) maximally accumulates
across the blood–brain barrier to levels only around 1–2% of
maximum plasma levels (Burri et al., 1993). This is sufficient
to clear trypanosomes with typical ‘wild-type’ sensitivities to
the drug. However, a drop in sensitivity of only a few fold
could render parasites in the CSF non-susceptible to these
levels (Brun et al., 2001; Burri and Keiser, 2001; de Koning,
2001b).
Side effects are severe. Convulsions and other neurological
sequelae can precede coma and death in the reactive
encephalopathy that afflicts 5–10% of treated patients.
Other adverse events are common. These include pyrexia,
headache, pruritis and thrombocytopaenia. Heart failure too
has been reported. Co-administration of corticosteroids (for
example, prednisolone) yields some protection against the
reactive encephalopathy (Pepin et al., 1989a). Thiamine
administration too can reportedly ameliorate melarsoprol’s
adverse events (Pepin and Milord, 1994). It was recently
shown (Szyniarowski et al., 2006) that melarsoprol enters
mammalian cells via a thiamine transporter, hence co-
administration of this vitamin may decrease melarsoprol
uptake into mammalian cells but not into trypanosomes.
Conjugation of melarsoprol in complexes might improve
toxicity by slowing release of the active principle (Gibaud
et al., 2002, 2005). Topical application to mouse models of
the disease was also successful and lowered toxicity
(Jennings et al., 1993; Atouguia et al., 1995). However, in
spite of the prospect of deriving improved melarsoprol
formulations, the drug’s reputation mitigates against taking
new arsenical derivatives forward.
Eflornithine
Background. Eflornithine (Figure 5) or D,L-a-difluoromethy-
lornithine (originally marketed as Ornidyl by Marion Merrell
Dow) is an analogue of the amino-acid ornithine and acts as
an inhibitor of the polyamine biosynthetic enzyme or-
nithine decarboxylase (ODC) (Bacchi et al., 1980; Phillips
et al., 1987; Bacchi and Yarlett, 1993). Eflornithine was first
developed as a potential antineoplastic agent; however, it
has still not been registered for use in therapy of cancer
(Gerner and Meyskens, 2004). The drug has activity against
T. b. gambiense, even in the late stage (Burri and Brun, 2003)
but against T. b. rhodesiense activity is restricted (Iten et al.,
1995). The usual regimen involves 100 mg kg1 body weight
at 6 h intervals (that is, 400 mg kg1 day1) by intravenous
infusion for 14 days. Shorter schedules and oral dosing have
so far given lower efficacy.
Mode of action and resistance mechanisms. Eflornithine has
similar affinity for both the mammalian and trypanosomal
ODCs (Phillips et al., 1988). Its specificity against the parasite
may arise because T. b. gambiense ODC is degraded and
replenished much more slowly than its mammalian counter-
part (Ghoda et al., 1990). A pulse of eflornithine thus
deprives trypanosomes of net polyamine synthesis for a
prolonged period compared with mammalian cells. Lack of
activity against rhodesiense parasites may relate to the
enzyme being more rapidly turned over in that subspecies
(Iten et al., 1997).
Polyamine biosynthesis inhibition is accompanied by an
increase in cellular levels of S-adenosyl methionine (Yarlett
and Bacchi, 1988), which causes inappropriate methylation
of proteins, nucleic acids, lipids and other cell components.
Trypanothione levels are also diminished after eflornithine
treatment (Fairlamb et al., 1987), which might render them
more susceptible to oxidative stress and other immunolo-
gical insult.
A functional immune system is required to kill the growth-
arrested trypanosomes (Bitonti et al., 1986b), which trans-
form into non-proliferating stumpy forms after exposure to
eflornithine. T. brucei lacks polyamine transporters rendering
them auxotrophic for polyamines (Fairlamb and Le Quesne,
1997) preventing by-pass of inhibition of polyamine bio-
synthesis, although the recent demonstration of variability
in sensitivity of different T. brucei strains to eflornithine in
rodents and a different potential of exogenous polyamines to
antagonize eflornithine’s activity (Nishimura et al., 2006)
could indicate some variability in the parasites’ capacity to
accumulate polyamines. One T. b. rhodesiense line selected
Figure 5 Structures of ornithine and eflornithine and some
trypanocidal nitroheterocycles.
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for eflornithine resistance showed enhanced capability to
import putrescine compared with sensitive lines (Bacchi
et al., 1993).
Eflornithine uptake in mammalian cells was reported to
involve simple diffusion across the membrane (Erwin and
Pegg, 1982). In T. brucei passive diffusion across the plasma
membrane in both bloodstream (Bitonti et al., 1986a) and
procyclic forms (Bellofatto et al., 1987) was proposed to
account for cell entry. However, the compound is rather
polar and unlikely to be lipid permeable. In the yeast,
Neurospora crassa, uptake is mediated via a cationic amino-
acid transporter (Davis et al., 1994). Moreover, another study
in procyclic trypanosomes (Phillips and Wang, 1987) showed
uptake to be temperature sensitive and to follow Michaelis–
Menten-type kinetics with an apparent Km of 244mM.
Although high concentrations (1 mM; Bitonti et al.,
1986a, b) and 20 mM (Phillips and Wang, 1987) of unlabelled
lysine, arginine and ornithine all failed to inhibit uptake,
lower doses were not tested and unphysiologically high
doses could lead to induction of other routes for eflornithine
uptake into the cell, leading to a masking of transporter-
mediated uptake. It is likely that uptake of eflornithine in
trypanosomes is carrier mediated. The trypanosome’s gen-
ome is replete with genes encoding amino-acid transporters
(Barrett and Gilbert, 2006) of which one or more could carry
eflornithine. Two reports of drug resistance (Bellofatto et al.,
1987; Phillips and Wang, 1987) in procyclic forms show that
drug uptake is diminished. Thus it seems probable that
resistance can relate to loss of, or changes to, eflornithine
transport into cells.
Pharmacology. The mean half-life in plasma following
intravenous injection of eflornithine is only in the order of
3 h, with 80% of the drug excreted unchanged in urine after
24 h (Haegele et al., 1981; Griffin et al., 1987). Little serum
protein binding occurs. Accordingly the drug must be given
in large doses by prolonged intravenous infusion.
In humans, reported CSF to plasma ratios vary between 0.1
and 0.9 (Milord et al., 1993; Burri and Brun, 2003; Na-
Bangchang et al., 2004) with the ratio towards the lower end
of that range more commonly reported. Eflornithine mono-
therapy apparently fails to cure the stage 2 mouse model,
perhaps because the drug fails to cross the blood–brain
barrier in rodents (Levin et al., 1983). In combination with
suramin, however, cure was possible, but only if mice were
kept in a 2 h light and 4 h dark regime (Jennings, 1993),
which relates to consumption of the drug in drinking water
being greatly enhanced (10–15 fold) in darkness (Romijn
et al., 1987).
In man, doses beyond 100 mg kg1 given orally failed to
lead to increased appearance of the drug in plasma, which
suggests that eflornithine is accumulated by a saturable
transporter. It is also probable that a transporter carries the
drug across the blood–brain barrier, where the yþ system
(the main cationic amino-acid transporter in mammals) is
the principal cationic amino-acid transporter (O’Kane et al.,
2006) and a likely candidate.
IC50 growth inhibitory values for eflornithine of 81–
693 mM (Zweygarth and Kaminsky, 1991) in vitro are very
poor when compared to the other trypanocidal drugs
(melarsoprol, suramin and pentamidine all have activity in
the nanomolar range). Oral dosing gave average plasma
levels of 234–528 mM and CSF levels at 22.3–64.7 mM in
patients receiving 100 or 125 mg kg1 (Na-Bangchang et al.,
2004). In vitro activities do not take into account the role of
the immune system in killing trypanosomes (Bitonti et al.,
1986b); however, the relative inefficacy of eflornithine,
coupled to its poor pharmacokinetic profile, renders the
drug far from ideal for use in a tropical setting and it is
unlikely that eflornithine would have been pursued had
protocols in use today, that begin with efficacy testing
against trypanosomes in vitro, been in place when the drug
was first explored for use against trypanosomiasis.
Side effects include fever, headache, hypertension, macu-
lar rash, peripheral neuropathy and tremor, gastrointestinal
problems including diarrhoea (Chappuis et al., 2005b). The
incidence and severity of these adverse reactions are
considerably lower than similar reactions in melarsoprol
therapy, and Médecins sans Frontières (MSF) are currently
promoting eflornithine as first-line treatment for stage 2
disease (Chappuis et al., 2005b; Balasegaram et al., 2006),
although the risk of resistance emerging must be taken
seriously.
Drugs in clinical trials
Pafuramidine maleate (DB289)
Background. The only new drug in advanced trials for
introduction to use against HAT is pafuramidine maleate
(DB289) (Figure 3). This O-methyl amidoxime prodrug
(Boykin et al., 1996; Ansede et al., 2004) is converted to the
diamidine furamidine (DB75) systemically.
Furamidine was first shown to be trypanocidal in the
1970s (Rane et al., 1976; Das and Boykin, 1977), but it offered
little or no benefit over pentamidine and was not pursued at
this time (Steck et al., 1982). The efficacy of pentamidine in
treatment of PCP, the incidence of which rose sharply as the
HIV/AIDS epidemic emerged in the 1980s, led to renewed
interest in di-cationic microbicides. Studies into the meta-
bolism of pentamidine (Berger et al., 1990, 1991, 1992;
Clement and Jung, 1994) revealed that the positive charges
of these molecules, which restrict intestinal absorbtion,
could be neutralized by chemical modification. Pentamidine
was converted to an amidoxime prodrug (Clement and
Raether, 1985; Clement, 2002) with trypanocidal activity
when given subcutaneously to mice. However, activity
against pneumocystitis was weak (Hall et al., 1998) and
furamidine synthesized as its prodrug, pafuramidine maleate
(Boykin et al., 1996), was far better in this context. Phase III
trials are currently underway for pafuramidine against PCP
(Yeates, 2003). Pafuramidine (100 mg twice per day for 5
days) also performed well in clinical trials against malaria
(Yeramian et al., 2005). However, a concern that widespread,
uncontrolled use of the drug as an antimalarial might
enhance the risk for selection of resistance to the drug in
trypanosomes has contributed to its being abandoned for
malaria. Since many diamidine compounds show superior
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in vitro activity against Plasmodium falciparum, it is hoped
that another candidate might emerge for malaria.
Mode of action and resistance mechanisms. As a diamidine it
would be anticipated that the modes of action and resistance
mechanisms for furamidine may overlap with those of
pentamidine and diminazene. Uptake of the compound to
high levels (Mathis et al., 2006) occurs principally via the
same P2 aminopurine transporter that carries other diami-
dines into cells (Lanteri et al., 2006). In a 3-day in vitro assay,
the activity of furamidine was greatly decreased against the
tbat1/P2 knockout cell line and a line selected for resistance
to the drug had lost the P2 transporter, through deletion of
its gene, confirming this as a main route of uptake (Lanteri
et al., 2006). However, these P2 defective cells fail to grow for
prolonged periods, even in relatively low concentrations of
drug, in vitro. Moreover, the P2 defective cells are only
marginally less sensitive than wild type when treated in mice
(Lanteri et al., 2006). Thus a secondary route of uptake, albeit
minor compared with P2, plays a significant role in the
pharmacology of the drug, and loss of the P2 transporter
alone is unlikely to lead to parasites developing resistance.
As furamidine is fluorescent, it has been possible to trace
its distribution in cells (Mathis et al., 2006). Within a minute,
UV fluorescence is detectable within the DNA containing
organelles (nucleus and kinetoplast). By 1 h, the drug
becomes visible within organelles believed to be acidocalci-
somes (Mathis et al., 2006). After 24 h exposure to 7.5 mM
drug, the fluorescence of the kinetoplast has disappeared, as
the drug appears to have caused disintegration of this
structure (Mathis et al., 2006). Damage to the mitochondrion
is also evident, leading to suggestions that the mitochon-
drion is a target for this drug. In yeast, furamidine (Lanteri
et al., 2004) like pentamidine (Ludewig et al., 1994), inhibits
the respiratory chain and it also acts as an uncoupler. The
mitochondrial inner membrane is also affected by furami-
dine in trypanosomes (Lanteri et al., unpublished), making it
tempting to speculate that mitochondrial disruption relates
to activity of this compound.
Pharmacology. In vitro, pafuramidine is over one thousand
fold less active against trypanosomes than furamidine
(Ansede et al., 2004). In vivo, however, furamidine is active
only when given by injection, while pafuramidine is active
in an oral formulation. This is because pafuramidine, but not
furamidine, crosses intestinal epithelium (Sturk et al., 2004)
in quantities sufficient to reach trypanocidal levels in blood.
The prodrug is metabolized by cytochrome P450 (CYP4F
isoforms in particular) and other metabolic enzymes (Ansede
et al., 2005; Saulter et al., 2005; Wang et al., 2006), through
demethylation followed by reduction, to the active diami-
dine. Furamidine does not cross the blood–brain barrier.
However a very close relative of furamidine, DB820, which
differs by the addition of a single nitrogen into one of the
phenyl rings (Figure 3) (Ismail et al., 2003), exerts trypano-
cidal activity in rodent models of stage 2 disease. The O-
methyl amidoxime prodrug of DB820, currently coded as
DB844, can be administered orally and still lead to the cure
of stage 2 mouse model (Ansede et al., 2005), the first orally
available compound to exert this effect.
Currently, little is published with regard to the clinical
development of pafuramidine for trypanosomiasis. However,
studies into metabolism, toxicology and pharmacokinetics
in animal models including mouse, rat, vervet monkey and
later cynomolgus monkey preceded its entry into phase I
clinical trials. These satisfied criteria enabling entry into
phase II trials in T. b. gambiense patients with stage 1 disease
(Yeates, 2003).
An initial open label, non-controlled trial focussed on a
site in Angola and one in the Democratic Republic of
Congo. Patients were treated with 100 mg of pafuramidine
given orally, twice daily for 5 days. Efficacy in that first
trial was 83% cure (93% of the 30 patients partaking in the
trial were cleared of parasites in blood and lymph 24 h
after the final dose. However, after 24 month follow-up a
further four patients had relapsed). The regimen was
then lengthened to a 10-day treatment for a phase IIb trial.
This has been more successful although follow-up must
continue until 2 years is complete. A multicentre phase III
trial, in which 250 patients will receive DB289 using non-
inferiority to injected pentamidine as the comparator, is
underway.
Some side effects were reported including intermittent
fever and pruritis. These were not serious and administration
of up to 600 mg in a single dose gave no adverse response.
Diminazene
Another diamidine, diminazene, is a registered veterinary
trypanocide (Kinabo, 1993; Peregrine and Mamman, 1993).
Unlicensed use in humans has been successfully attempted
(Pepin and Milord, 1994). Dose of drug and time of exposure
are important in determining the trypanocidal effect of
diminazene. Iten et al. (1997) showed that exposure of
trypanosomes to 10 mg ml1 of diminazene for less than
1 min committed the cells to death (although it took several
days before the cells died). At 1mg ml1, the exposure time
needed for death rose to 15 min, while at 0.1 mg ml1 cells
needed to be exposed for 24 h before proceeding to a delayed
death.
The drug enters trypanosomes via the P2 transporter
(Barrett et al., 1995; Ross and Barns, 1996; de Koning et al.,
2004; Witola et al., 2004) and tbat1 gene knockout cells
(Matovu et al., 2003) are resistant to diminazene. Alternative
transporters, such as HAPT1 and LATP1, play a less
important role in entry of this compound than they do for
pentamidine, although the drug does continue to enter
TbAT1/P2 defective cells albeit very slowly (de Koning et al.,
2004), and in in vitro assays the P2-deficient cells retain
sensitivity to diminazene in the low micromolar range
(Matovu et al., 2003).
Pharmacokinetic properties of diminazene deviate widely
from pentamidine. For example, the volume of distribution
is much lower in animals studied (probably due to less
protein binding and tissue retention) (Peregrine and Mam-
man, 1993). Given that the orally available pafuramidine
will complete phase III trials soon, it is this latter compound
that is more likely to be approved than diminazene, which
will be retained as a veterinary trypanocide. The possibility
of selecting parasites that lack the P2 transporter in
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development of diminazene resistance (Barrett et al., 1995) is
of concern (de Koning, 2001a, b), especially where T. b.
rhodesiense is present at significant levels in livestock (Barrett,
2001). The risk of selecting for P2 transporter-defective
parasites that might enter humans must be considered
before implementing any drug campaigns against veterinary
trypanosomiasis.
Nifurtimox
Background. Nifurtimox, marketed as Lampit, is produced
by Bayer, provided free to WHO and distributed by MSF for
use in trials in HAT therapy or for compassionate use in cases
of melarsoprol failure. Success as monotherapy has report-
edly been limited (50–80% cure) against T. brucei gambiense
(Janssens and Demuynck, 1977; Pepin et al., 1989b) but its
use, particularly in combinations (Moens et al., 1984;
Jennings, 1991), is of increasing interest, as reports of
treatment failure with arsenical monotherapy rise. Recent
trials in combination with eflornithine show great promise
(Priotto et al., 2006).
Mode of action. Single electron reduction of the nitro group
of nifurtimox generates a free radical, which may interact
with cellular constituents or generate reduced oxygen
metabolites believed to cause parasite death (Docampo and
Moreno, 1986; Enanga et al., 2003). With a reduction
potential of 260 mV, nifurtimox is relatively easily reduced
in many cell types (Viode et al., 1999) but a typical
prokaryote-related type 1 nitroreductase identified in the
trypanosome’s genome is likely to play a role in activation
of nifurtimox and other nitroheterocycles (S Wilkinson,
London School of Hygiene and Tropical Medicine, personal
communication).
Numerous nitroheterocycles have been demonstrated to
have potent activity against trypanosomes. Nitrofurazone (a
nitrofuran) entered human trials in the mid-twentieth
century, but toxicity issues halted its development (Apted,
1970). Several 2-substituted 5-nitroimidazoles (Jennings,
1991) were shown to be efficacious and cured the stage 2
mouse model when co-administered with suramin. The
nitroimidazole–thiazole, megazol, too was active when
administered with suramin in stage 2 mouse and rat models
(Enanga et al., 1998; Darsaud et al., 2004) and also able to
cross the blood–brain barrier in significant quantities in a
primate model (Enanga et al., 2000). A group of 5-nitro-2-
furancarbohydrazines were also recently shown to possess
substantial trypanocidal activity (Millet et al., 2002).
As host cell toxicity, particularly genotoxicity, has miti-
gated against development of antimicrobial nitrohetero-
cycles, the possibility of selectively targeting melamine-
coupled nitroheterocycles to trypanosomes, via the P2
aminopurine transporter, was investigated (Stewart et al.,
2004; Baliani et al., 2005). Several compounds were identi-
fied with excellent trypanocidal activity and they appear to
enter via routes in addition to P2. The possibility of targeting
trypanocides to trypanosomes via transporters has been
covered extensively in a recent review (Barrett and Gilbert,
2006).
Pharmacology. Serum levels are reportedly low when nifur-
timox is given orally, peaking 1–3 h after administration of a
single 15 mg kg1 dose, reaching a maximum of around 4 mM
in healthy subjects (Paulos et al., 1989). Clearance is fast with
a plasma elimination half-life of around 3 h (Paulos et al.,
1989). The drug can accumulate across the blood–brain
barrier (Burri et al., 2004) to levels around half of those found
in plasma. African trypanosomes are not very susceptible to
nifurtimox (IC50 values of around 5 mM compared with 10 nM
for melarsen oxide in a typical in vitro assay (Enanga et al.,
2003)). This probably explains the drug’s limited efficacy as
monotherapy.
Toxic effects to the central and peripheral nervous systems
have been reported (Castro et al., 2006) and rats given high
doses of the drug showed increased risk of cancer (Steinhoff
and Grundmann, 1972). Typical regimens used for T. cruzi
infections (15 mg kg1 over 60 days) lead to nausea, vomiting
and other problems. At 15 mg kg1, additional adverse affects
including polyneuropathy were evident and the gastroin-
testinal problems more pronounced and more frequent
(Pepin et al., 1992).
Combinations
Combination chemotherapy is becoming the preferred route
of administration of antimalarial compounds in the hope of
diminishing the probability of selecting for drug-resistant
mutants (Kremsner and Krishna, 2004). Treatment failure is
also a growing problem in trypanosomiasis therapy (Brun
et al., 2001). There are other reasons for using drugs in
combination. Synergistic effects can permit the lowering of
doses for the combination partners thus reducing adverse
effects. Jennings (1993) pioneered work into seeking syner-
gistic effects with trypanocidal drugs in rodent models.
Suramin, acts synergistically with many drugs. For example,
administration of suramin 15 min before topical administra-
tion of melarsoprol led to good cure rates of the stage 2
mouse model. Suramin also altered the volume of distribu-
tion and pharmacokinetics of the experimental trypanocide
megazol in mice (Enanga et al., 1998), possibly because it
inhibits P-glycoprotein pumps (Buxbaum, 1999) that play
key roles in maintaining the blood–brain barrier and also in
removing xenobiotics through the renal system. Pre-treat-
ment with other agents that induce changes to renal
clearance or blood–brain barrier permeability could also
influence efficacy of trypanocides in vivo (Croft, 1999).
Recent clinical trials using eflornithine
(400 mg kg1 day1) for 7 days in two periods of infusion
(rather than 14 days with four infusions) and nifurtimox at
15 mg kg1 for 10 days have yielded cure rates as high as 98%
(Priotto et al., 2006). Other combinations (melarsoprol and
eflornithine or melarsoprol and nifurtimox) were considered
too toxic to pursue (Priotto et al., 2006). Nifurtimox exerts its
activity through induction of oxidative stress (Docampo and
Moreno, 1986; Enanga et al., 2003) while eflornithine
diminishes levels of trypanothione, a key metabolite used
in protecting against oxidative stress, thus it is possible that
these drugs synergize at the level of parasite killing.
Since melarsoprol treatment failure rates have been
increasing, and because resistance to eflornithine is relatively
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easy to select in the laboratory (Bellofatto et al., 1987;
Phillips and Wang, 1987; Bacchi et al., 1993), in the absence
of alternative drugs every effort should be taken to delay the
onset of resistance to eflornithine in the field. The use of a
nifurtimox–eflornithine combination presently offers pro-
mise in this regard.
Phamacological re-engagement with HAT
By the end of the twentieth century it had been widely
accepted that industrial input to neglected diseases like HAT
was not viable on purely commercial grounds. For some
diseases, like malaria and tuberculosis, with prevalences
greatly in excess of HAT, public–private partnerships, the
Medicines for Malaria Venture (http://www.mmv.org) and
The Global Alliance for TB Drug Development (TB Alliance)
(http://new.tballiance.org/home/home-live.php), were
founded in 1999 and 2000, respectively.
For HAT, however, the situation reached a low point at the
turn of the Century (Barrett, 1999). The prevalence of the
disease had reached alarming levels. Treatment failures with
melarsoprol were reported in several foci and Aventis, the
manufacturer of that drug, found themselves confronted
with the dilemma of whether to continue producing, at a
loss, one of the most toxic compounds known to the
pharmacopoeia, or to drop production leaving patients to
die. MSF and other non-governmental organizations were
establishing centres in many African countries to deal with
the crisis and drugs for HAT soon made it to the forefront of
MSF’s campaign on ‘Access for Essential Medicines’ (Pécoul
et al., 1999). WHO were engaged in an apparently fruitless
quest to find a manufacturer for eflornithine after Hoechst
Marion Roussel (which was later incorporated into Aventis)
had abandoned production in the 1990s.
Then, in 2000, an extraordinary event occurred. Gillette
launched eflornithine, made by Bristol-Myers Squibb, as a
topical formulation under the trade name Vaniqa, to
suppress the growth of unwanted facial hair. It was at this
point that Aventis, now Sanofi-Aventis, were persuaded to
produce the drug free for WHO to distribute to national
programmes involved in HAT therapy. Aventis also agreed to
provide pentamidine and melarsoprol gratis for an initial
period of 5 years (2001–2006) and Bayer joined in by
donating suramin and nifurtimox too. Aventis have recently
extended their support for 5 more years (until 2011), and
surveillance and research were also stepped up under the
WHO–Aventis deal. In addition to the role of WHO other
initiatives are playing a role.
In 1999, The Bill and Melinda Gates Foundation was
established and has set about funding, to unprecedented
levels, initiatives in global health and education. With an
endowment fund of $31.7 billion the Foundation has
transformed the environment with regard to funding in
several tropical diseases. Late in 2000, the Foundation started
funding a group of researchers under the leadership of the
University of North Carolina at Chapel Hill (UNC) to
develop pafuramidine for HAT. As discussed earlier, there is
a genuine hope that the drug will successfully complete trials
within 2 years and plans are already being drawn up for its
manufacture and distribution. In addition to the develop-
ment of pafuramidine, the UNC-led consortium also
received funds to seek new drugs for visceral leishmaniasis
and the consortium was refunded in 2006 to continue
searching for new drugs for late-stage HAT and visceral
leishmaniasis, as well as to take pafuramidine through
clinical trials. Other initiatives are also underway. The
Special Programme for Research and Training in Tropical
Diseases of WHO (WHO/TDR) has long fought for new drugs
for HAT and other tropical diseases. Following consultation
initiated through MSF’s ‘Access Campaign’ (Trouiller et al.,
2002), the Drugs for Neglected Diseases initiative (DNDi)
(http:www.dndi/org), a Public Private Partnership, was
founded in 2003, to discover and develop new drugs to treat
trypanosomatid diseases (HAT, Chagas disease and leishma-
niases). The UK’s Wellcome Trust has remained a major
player in the field of trypanosomiasis research. They
provided much of the funding required to sequence the
trypanosome’s genome (Berriman et al., 2005). With
the genome known, every potential drug target within the
trypanosome is now accessible. Gene knockout (Barrett et al.,
1999) and RNA interference can both be used to provide
evidence as to whether genes, and the proteins they encode
are essential and thus validated drug targets. A natural
progression has been for the Wellcome Trust to establish a
screening centre at the University of Dundee, where a library
of chemicals (containing an initial set of 62 000 compounds,
selected for lead drug-like criteria) is being screened system-
atically for activity against validated targets (http://
www.drugdiscovery.dundee.ac.uk). High-throughput screen-
ing is also underway at the Sandler Centre at the University
of California, San Franciso (http://www.ucsf.edu/mckerrow/
slide.html).
The in vitro model system to test trypanocidal efficacy in
operation at a number of centres, the largest of which were
originally supported by WHO/TDR (http://www.who.int/tdr/),
allows rapid screening of tens of thousands of compounds
for trypanocidal activity. These centres offer pharmaceutical
companies an opportunity to re-engage with diseases like
HAT without having to set up in-house facilities. Pfizer
Animal Health, for example, has recently initiated a screen-
ing programme with their compound libraries in collabora-
tion with WHO/TDR against a range of tropical diseases,
including HAT. DNDi has linked up with agencies holding
natural product libraries to enter similar screens. DNDi is
also pursuing other lead compounds by bringing together
groups of investigators in consortia to proceed through the
development process. Potent trypanocides discovered in
these screens can then enter rodent models of stages 1 and
2 disease to test in vivo efficacy.
The surge in activity in research into new drugs for HAT
should see the emergence of numerous lead compounds over
the next few years. A bottleneck in drug development,
however, is likely to appear at this point. Committed
chemists and pharmacologists must join the venture to
optimize leads. The narrowest bottleneck will, however,
involve taking compounds into clinical trials.
In addition to the advancement of pafuramidine through
phase III trials, the UNC-led consortium is funded to seek
new agents for stage 1 and, especially, stage 2 HAT. In
addition to in-house chemistry efforts, novel compounds
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emerging from other screening programmes will be con-
sidered by the UNC group to take through the latter stages of
development, drawing on the experience gained in the
development of pafuramidine. The development of pafur-
amidine provides a good model on the kinds of interaction
needed to take a compound through the whole-development
process. A tightly knit, multidisciplinary, multinational
consortium, involving academic and industrial input to
cover all aspects of drug development has been necessary.
The project was founded on the premise that diamidines are
highly trypanocidal and that chemical modification could
allow changes that effect efficacy and pharmacokinetics in a
manner to optimize use. The consortium involves chemists
who can produce new compounds that are screened in assays
for trypanocidal activity and for in vivo efficacy (and against
drug-resistant trypanosomes). Uptake into trypanosomes
and their ability to bind putative targets is also tested in a
systematic fashion. Iterative syntheses based on structure–
activity relationships are possible. Hit compounds can be
tested for efficacy and pharmacokinetic properties in rodent
and simian models, in an academic setting, with the best
compounds then sent for GLP testing in an industrial
setting.
For pafuramidine itself, its potential use against PCP
meant that phase I clinical trials had already been completed
by the time the UNC-led consortium commenced their effort
on trypanosomiasis. This enabled its rapid introduction into
phase II trials against HAT patients. Fortunately, investiga-
tors from the Swiss Tropical Institute had recently been
engaged with a series of centres in Africa to test the new
melarsoprol short course (Burri et al., 2000), thus trials in
these centres, under conditions that came as close as is
possible, in this environment, to Good Clinical Practise
became a possibility. Clinical trials within HAT affected areas
offer great challenges. For example, in conditions where
electricity supplies are often absent, facilities enabling
constant temperature storage of compounds become im-
possible. Biochemical and physiological tests considered
routine in a hospital in the west cannot be conducted and
so on. The pafuramidine project, having received appro-
priate funding for clinical trials and also having garnered
support from national programmes and WHO, has managed
to proceed remarkably smoothly.
The number of people capable of conducting such trials is
limited. Moreover, the recent downturn in the incidence of
HAT (Anonymous, 2006; Barrett, 2006), coupled to the
requirement for strict exclusion criteria to reach objective
conclusions from trials, offers a very major problem. Patients
located in the vicinity of the few centres capable of
conducting satisfactory clinical trials are presently in short
supply. Logistical problems restrict the ability to reach other
areas and to recruit patients into trials relatively far from
their homes. Diagnostics, active case finding and the
establishment of new facilities in remote areas where the
disease is most prevalent will be required to ensure that
meaningful clinical trials are possible once compounds begin
to emerge over the next 2–10 years.
The problem has been recognized and the Bill and Melinda
Gates Foundation has recently funded the Foundation for
Innovative New Diagnostics (http://www.finddiagnostics.
org) and WHO to seek new diagnostics. With a view to
ensuring that any new drugs can be targeted most efficiently
to those who need them, the UNC-led consortium has also
initiated efforts to identify the precise extent and distribu-
tion of HAT, building on statistics collected by the WHO over
many years. DNDi along with other key agencies, including
WHO, has been formulating a ‘platform for clinical trials’ to
standardize and coordinate efforts.
Unprecedented activity in the area of drug discovery for
HAT is underway, plans to help products through develop-
ment bottlenecks are being put in place and there is
currently, for the first time in a generation, great optimism
that novel drugs for HAT will emerge over the next decade.
Conclusions
HAT has become a cause célèbre among those concerned with
the economic factors that have led to diseases of the world’s
poorest populations becoming neglected in terms of new
drug development. The agents that are currently available as
anti-trypanosomals are generally unsatisfactory due to a
combination of their low efficacy, dangerous side effects and
difficulty in administration. In the twenty-first century,
however, the situation is changing. Increased knowledge
about the trypanosomal genome has already led to the
identification of novel drug targets. This development has
occurred in parallel with the emergence of funding agencies
committed to the elimination of sleeping sickness through
coherent and integrated research projects. There is now
unprecedented optimism that new drugs active against both
stage 1 and stage 2 of the disease will emerge over the next
decade.
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